论文部分内容阅读
对25例急性髓性白血病(AML)试用小剂量阿糖胞苷(Ara-C)和鬼臼乙叉甙(VP16)观察其疗效及副作用。按FAB分型M_03例,M_15例,M_210例,M_43例,M_51例,低增生白血病3例。包括初治12例,初治无效(难治)6例。复发7例。年龄范围19～85岁(中数值63岁),男女比11:14。复治病例原先均曾用过BHAC-DMP方案治疗。高龄(>65岁)(11例),重症感染(8例),心机能(NYHA>Ⅲ度)(10例)或呼吸机能不全(动脉氧分压<60托)(5例),对血小板输注有抗拒(3例)。拒绝或难以施行强化疗(包括蒽环类药物)(3例)为采用小剂量Ara-C/VP16的治疗对象。小
The efficacy and side effects of Ara-C and VP16 were observed in 25 cases of acute myeloid leukemia (AML). According to FAB classification M_03 cases, M_15 cases, M_210 cases, M_43 cases, M_51 cases, 3 cases of hypoplasia. Including the initial treatment of 12 cases, initial treatment was invalid (intractable) in 6 cases. 7 cases of recurrence. The age range is 19 to 85 years old (the median value is 63 years old), and the male to female ratio is 11:14. Retreatment cases have all been treated with the BHAC-DMP regimen. Elderly (>65 years old) (11 cases), severe infection (8 cases), cardiac function (NYHA> III degree) (10 cases) or respiratory insufficiency (arterial oxygen partial pressure <60 Torr) (5 cases), for platelets Infusion resistance (3 cases). Rejected or difficult to perform strong chemotherapy (including anthracycline) (3 cases) was treated with a small dose of Ara-C/VP16. small